Amgen (AMGN) options expected to be active after reporting Repatha data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mail
Get Alerts AMGN Hot Sheet
Price: $438.34 -0.14%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: +5.2%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: +5.2%
Join SI Premium – FREE
Amgen (NASDAQ: AMGN) March call option implied volatility is at 90, March weekly is at 41, April is at 26; compared to its 52-week range of 16 to 30 into releasing data for its 27,564-patient Repatha cardiovascular outcomes study,
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Thermo Fisher Scientific (TMO) call put ratio 1 call to 1.9 puts with a focus on November 610 puts
- Lam Research (LRCX) call put ratio 1.9 calls to 1 put into quarter results
- Comcast (CMCSA) call put ratio 1.3 calls to 1 put into quarter results
Create E-mail Alert Related Categories
Options, Trader TalkRelated Entities
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
